证券代码：300633 证券简称：开立医疗 编号：2026-001 深圳开立生物医疗科技股份有限公司 投资者关系活动记录表 投资者关 系活动类 别 ☑ 特定对象调研 □ 媒体采访 □ 新闻发布会 □ 现场参观 ☑ 电话会议 □ 分析师会议 □ 业绩说明会 □ 路演活动 □ 一对一沟通 □ 其他 参与单位 名称 东吴证券、国海证券、博时基金、鹏华基金、人保养老、中航基金、 中金资本 时间 2026 年 3 月 1-5 日 地点 公司会议室 上市公司 接待人员 董事会秘书李浩先生 投资者关 系活动主 要内容介 绍 问：公司各产品线在 2025 年国内中标情况？ 答：2025 年，国内医疗终端的招标开始复苏，在此背景下，公 司各产品线凭借良好的产品力均取得较好成绩。据公司初步统计以 及第三方数据验证，2025 年公司超声、内镜、外科、ivus 产品终端 中标金额均明显增长，合计中标金额取得历史新高；各细分领域， 从中标数据看，公司超声产品市场地位稳健，内镜市场份额显著提 升，外科、ivus 产品的中标排名快速前进，四条业务线在细分领域 均处于国内前列。 由于过去医疗行业整顿原因，公司报表端收入相比中标有所延 迟，但 ...

2026年2月27日，国家药品监督管理局公布了 创新医疗器械特别审查申请审查结果公示（2026年第4号） ， 有 4款产品 进入创新通道 。 | | | 2. 神经外科手术导航系统 申请人 ：北京联影智融医疗科技有限公司 北京联影智融医疗科技有限公司是联影医疗技术集团旗下医疗科技企业，致力于为临床提供创新医疗产品与解决方案。公司聚焦预防、诊断、治疗和康复等临床应 用场景，通过自主研发和产业化推进智能医疗设备及系统的落地，包括手术导航系统、辅助设备及智能诊疗系统等，服务医院临床和医生诊疗工作。联影智融在联 影集团医疗生态框架支持下，旨在提升医疗科技整体能力，推动智能医疗应用在全球范围的普及。 1.胰腺病变CT图像辅助分诊软件 申请人 ： 阿里巴巴达摩院（北京）科技有限公司 阿里巴巴达摩院（北京）科技有限公司成立于2017年11月，是阿里巴巴集团设立的科研与技术创新机构，在北京注册登记运营，主营科技推广与应用服务。达摩院 以"探索科技未知、以人类愿景为驱动力"为使命，聚焦基础科学和前沿技术研究，在人工智能、机器学习、数据计算、视觉计算等核心领域开展长期研发，并推动 科研成果向产业实践和产品化落地。达摩院在医疗影像 ...

2月27日的资金流向数据方面，主力资金净流出1.13万元，占总成交额0.02%，游资资金净流出215.25万 元，占总成交额2.96%，散户资金净流入216.38万元，占总成交额2.98%。 该股主要指标及行业内排名如下： 证券之星消息，截至2026年2月27日收盘，开立医疗(300633)报收于27.09元，上涨1.35%，换手率 0.62%，成交量2.69万手，成交额7260.6万元。 近5日资金流向一览见下表： 该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019 ...

内容概况：在"千县工程"与"设备更新行动"的政策推动下，以县级医院为代表的基层医疗机构正在加速 填补其精准诊疗能力的短板。例如，围绕"消化道肿瘤早筛"和"胰腺等复杂疾病诊断"的需求，正在转化 为实实在在的设备采购订单。作为融合光学内镜与高频超声成像的高端医疗设备，中国超声胃镜行业正 处于市场规模稳健增长阶段。2024年，中国超声胃镜行业市场规模约为1.45亿元，同比增长8.21%。 相关上市企业：开立医疗（300633） 相关企业：广东奥迪威传感科技股份有限公司、浙江嘉康电子股份有限公司、江苏江佳电子股份有限公 司、上海韦尔半导体股份有限公司、歌尔微电子股份有限公司、长飞光纤光缆股份有限公司、亨通光电 股份有限公司、烽火通信科技股份有限公司、通鼎互联信息股份有限公司、中天科技股份有限公司、海 光信息技术股份有限公司、龙芯中科技术股份有限公司、中微半导体设备（上海）股份有限公司、京东 方科技集团股份有限公司、深南电路股份有限公司 关键词：超声胃镜、超声胃镜市场规模、超声胃镜行业现状、超声胃镜发展趋势 一、行业概述 超声胃镜是内镜技术与超声技术融合的先进医疗设备，通过在内镜前端或活检通道内置微型高频超声探 头，在 ...

该股主要指标及行业内排名如下： 证券之星消息，截至2026年2月25日收盘，开立医疗(300633)报收于26.98元，上涨1.35%，换手率 0.7%，成交量3.03万手，成交额8182.98万元。 2月25日的资金流向数据方面，主力资金净流出247.16万元，占总成交额3.02%，游资资金净流入592.66 万元，占总成交额7.24%，散户资金净流出345.5万元，占总成交额4.22%。 近5日资金流向一览见下表： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有4家机构给出 ...

深圳开立生物医疗科技公司业务经理表示："依托班列的稳定服务和定制化方案，我们的精密医疗设备 才能安全、准时送达欧洲客户手中。" 平湖南综合物流枢纽营业部经理罗练林表示："我们将构建更高效、便捷的国际物流平台，进一步降低 企业跨境贸易的综合成本。" 本报深圳2月24日电(记者李刚)2026年农历正月初一早上8时许，一声汽笛在深圳平湖南站鸣响，满载家 电、电子产品及跨境电商包裹的X8426次中欧班列，迎着新春朝阳启程，奔赴满洲里口岸，预计14天后 抵达俄罗斯、波兰等国家。 这趟新春首发的中欧班列是粤港澳大湾区外贸物流"开年第一单"。自2020年8月18日首趟"湾区号"中欧 班列从深圳开往德国杜伊斯堡以来，截至目前已累计开行975列，运送货物超9万标箱，货值突破31亿美 元，线路从1条增至27条常态化线路，覆盖德国、俄罗斯等47个国家和地区，服务大湾区企业超7000 家。 ...

证券之星消息，截至2026年2月24日收盘，开立医疗(300633)报收于26.62元，上涨0.08%，换手率 0.62%，成交量2.7万手，成交额7246.33万元。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额 ...

Core Insights - Mayo Clinic has announced six cross-disciplinary collaborations, indicating a shift from being mere technology consumers to becoming organizers of innovation within the healthcare ecosystem [2][4][19] - The collaborations span various technologies, including wearable oxygen monitoring, AI imaging protocols, digital outpatient services, and gene testing, showcasing a significant expansion beyond traditional hospital procurement [2][4] Group 1: Demand Structure Transformation - The demand logic in hospitals is undergoing a three-tier leap, moving from single-point solutions to system capability building [4][5] - The first leap involves a shift in focus from "single-use effectiveness" to "long-term data value," emphasizing the importance of data systems in future medical devices [6][10] - The second leap sees hospitals transitioning from end-users to co-creation partners, indicating that those who define the technology path will likely shape the future market [8][12] - The third leap reflects a change from short-term procurement to long-term ecological collaboration, with hospitals now evaluating partnerships based on ecosystem development rather than one-time transactions [12][13] Group 2: Mayo Clinic's Strategic Layout - The Mayo Clinic Platform is not just a technology platform but a foundational infrastructure for innovation, allowing hospitals to create an innovative environment and select partners to define technology paths [14][15] - The Center for Digital Health at Mayo Clinic plays a strategic role, emphasizing that digital capabilities are core competitive advantages rather than mere support tools [15][18] Group 3: Global Trends and Driving Factors - A similar transformation is occurring globally, with hospitals shifting from passive technology acceptance to active innovation organization [19][20] - Four key driving factors include: 1. Medical data becoming a strategic asset, no longer viewed as a byproduct but as a resource for innovation [20] 2. AI entering substantive clinical applications, requiring continuous training and validation in real-world settings [21] 3. Increased demand for real-world evidence, positioning hospitals as critical nodes for evidence generation [21] 4. Dual pressures of quality and efficiency, making technological innovation a necessity rather than an option [21] Group 4: Systemic Impact on Medical Device Companies - The logic of product definition is evolving, requiring consideration of data dimensions, system integration capabilities, and collaborative support for multi-center research [22] - Market organization capabilities must upgrade, shifting from promotional execution to strategic dialogue and long-term partnerships [23] - The collaboration model is fundamentally changing from supplier relationships to innovation partnerships, emphasizing value co-creation over product supply [24] Group 5: Strategic Opportunities and Competitive Positioning - The current period is a critical window for companies to adapt to the evolving demand structure, as hospitals seek long-term partners that fit their innovation ecosystems [25][28] - Three key capabilities will determine future competitive positioning: data value creation, ecosystem integration, and collaborative co-creation [27][28]

Core Viewpoint - A newly approved non-invasive treatment for locally advanced pancreatic cancer, utilizing a wearable device to continuously deliver electric fields that disrupt tumor cell division, has gained attention. This treatment, approved by the FDA for use in the U.S., is not yet available in China but offers insights for domestic professionals [2]. Group 1: Treatment Mechanism - The Optune Pax system employs Tumor Treating Fields (TTFields) technology, delivering low-intensity alternating electric fields to the tumor area via electrode arrays attached to the skin [3]. - The core mechanism of action is that the electric field affects rapidly dividing cancer cells while having a limited impact on normal cells, which divide more slowly [4][5]. Group 2: Device Characteristics - Optune Pax is a lightweight and portable system, allowing patients to receive treatment while maintaining daily activities [6]. - The device applies physical forces to charged cellular structures, disrupting spindle formation during mitosis, blocking chromosome separation, and leading to cancer cell death [7]. Group 3: Clinical Trial Results - The approval of Optune Pax is based on the pivotal Phase III clinical trial PANOVA-3, which demonstrated a significant improvement in overall survival [9]. - In the intention-to-treat population, the median overall survival was 18.3 months for the treatment group compared to 15.1 months for the control group, indicating a clinically meaningful improvement [10]. - The one-year survival rate was 68.1% for the treatment group versus 60.2% for the control group [11]. - Patients experienced delayed progression of pain and improved quality of life indicators, with the treatment showing good overall tolerability [12]. Group 4: Challenges and Future Considerations - Despite positive clinical trial results, real-world application faces challenges, including balancing efficacy and treatment burden, which will directly impact its adoption [17]. - Key observations for future development include the need for real-world data to validate the long-term value of TTFields in pancreatic cancer treatment [18]. - The treatment landscape for pancreatic cancer has seen little innovation over decades, making this development noteworthy [19].

Core Viewpoint - The stock of Kaili Medical (300633) has shown a decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][2]. Group 1: Stock Performance - As of February 13, 2026, Kaili Medical's stock closed at 26.6 yuan, down 1.04% with a turnover rate of 0.48% and a trading volume of 20,900 lots, amounting to a transaction value of 56.07 million yuan [1]. - Over the past five days, the stock has experienced fluctuations, with a notable drop on February 13, where the main capital saw a net outflow of 224.51 million yuan, accounting for 4.0% of the total transaction value [2]. Group 2: Financial Metrics - Kaili Medical's total market capitalization is 11.51 billion yuan, slightly above the industry average of 10.91 billion yuan, ranking 30th out of 129 companies in the medical device sector [3]. - The company reported a net profit of 33.51 million yuan, which is significantly lower than the industry average net profit of 208 million yuan, placing it 79th in the industry ranking [3]. - The company's gross margin stands at 60.36%, which is higher than the industry average of 51.01%, indicating a strong pricing power in its products [3]. Group 3: Recent Financial Performance - For the first three quarters of 2025, Kaili Medical's main revenue reached 1.459 billion yuan, reflecting a year-on-year increase of 4.37%, while the net profit decreased by 69.25% to 33.51 million yuan [3]. - In the third quarter of 2025, the company achieved a quarterly revenue of 495 million yuan, up 28.42% year-on-year, but reported a negative net profit of -13.52 million yuan, despite a year-on-year increase of 78.05% [3]. Group 4: Analyst Ratings - In the last 90 days, four institutions have provided ratings for Kaili Medical, with three giving a "buy" rating and one an "accumulate" rating, indicating a generally positive outlook from analysts [4].